Evidence map›Paper›PMID 41082230›Full record

ArticleJAMA network open2025

Breast Cancer Incidence Rates in Ghanaian and US Black Women From 2013 Through 2015.

Brittny C Davis Lynn, Jonine D Figueroa, Dennis Laryea, Fred Kwame Awittor, Naomi O Ohene Oti, Quiera S Booker, Lawrence Edusei, Nicolas Titiloye, Ernest Adjei, Beatrice Wiafe Addai and 16 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Brittny C Davis LynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Jonine D FigueroaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Dennis LaryeaKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Fred Kwame AwittorKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Naomi O Ohene OtiKorle Bu Teaching Hospital, Accra, Ghana.
Quiera S BookerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Lawrence EduseiKorle Bu Teaching Hospital, Accra, Ghana.
Nicolas TitiloyeKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Ernest AdjeiKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Beatrice Wiafe AddaiPeace and Love Hospital, Kumasi, Ghana.
Robertson AdjeiGhana Statistical Service, Accra, Ghana.
Lucy T AfriyieGhana Statistical Service, Accra, Ghana.
Joel YarneyKorle Bu Teaching Hospital, Accra, Ghana.
Daniel AnsongKwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Seth WiafeLoma Linda University, Loma Linda, California.
Thomas AhearnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Verna VanderpuyeKorle Bu Teaching Hospital, Accra, Ghana.
Florence DedeyKorle Bu Teaching Hospital, Accra, Ghana.
Louise A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Baffour AwuahKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Joe Nat Clegg-LampteyKorle Bu Teaching Hospital, Accra, Ghana.
Mustapha AbubakarDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Montserrat Garcia-ClosasCancer Epidemiology and Prevention Unit, Institute for Cancer Research and Imperial College, London, United Kingdom.
Richard BiritwumUniversity of Ghana, Accra, Ghana.
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Ghana Breast Health Study Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Uncertainty exists about whether women of West African ancestry have increased rates of estrogen receptor (ER)-negative breast tumors, which commonly have earlier age onsets than ER-positive tumors and are aggressive. High-quality population-based studies in Africa with tumor pathology data are generally unavailable, and there is speculation that younger population age structures may explain the increased frequencies of reported ER-negative tumors. Objective: To estimate age-standardized and age-specific rates of ER-negative breast cancer among Ghanaian women and non-Hispanic Black and non-Hispanic White women in the US. Design, Setting, and Participants: This cross-sectional study used 2013 through 2015 data from a population-based case-control study conducted in 2 metropolitan areas of Ghana, Accra and Kumasi, to estimate ER-specific breast cancer incidence rates among women 18 to 74 years of age. Incidence rates were recovered by applying sampling weights for controls calculated by district, 5-year age groups, and nonresponse rates from the 2010 census-based enumeration area listings. US Breast Cancer Registry data were retrieved from 17 registries in the Surveillance, Epidemiology, and End Results (SEER) program for non-Hispanic Black and non-Hispanic White women with breast cancer 20 to 74 years of age. Analyses were conducted January 2020 through May 2025. Exposures: Age, sex, race and ethnicity, ER tumor status, and country (US and Ghana). Main Outcomes and Measures: For each of 3 populations, crude, age-standardized, and age-specific breast cancer incidence rates were calculated overall and by ER status. Results: Analyses were performed for 1071 women (age range, 18-74 years; 468 [51%] ER-negative) in Ghana and 18 321 non-Hispanic Black women (age range, 20-74 years; 5117 [29%] ER-negative) and 103 227 non-Hispanic White women (age range, 20-74 years; 15 040 [15%] ER-negative) in SEER. From 2013 through 2015, ER-negative age-standardized incidence rates were 42.3 (95% CI, 38.7-46.3) per 100 000 women for Ghanaian participants and 43.1 (95% CI, 42.0-44.3) per 100 000 for US non-Hispanic Black women, both higher rates than that of 24.0 (95% CI, 23.6-24.4) per 100 000 for US non-Hispanic White women. ER-positive age-standardized incidence rates were 42.1 (95% CI, 38.4-46.1) per 100 000 women for Ghanaian participants, 105.4 (95% CI, 103.6-107.3) per 100 000 for non-Hispanic Black women, and 128.5 (95% CI, 127.9-129.7) per 100 000 for non-Hispanic White women. Conclusions and Relevance: In this cross-sectional study of Ghanaian and US non-Hispanic Black and non-Hispanic White women with breast cancer, age-standardized tumor incidence rates for women with ER-negative tumors in Ghana were similar to those for US non-Hispanic Black women, and both rates were higher than for US non-Hispanic White women. This finding may suggest increased susceptibility requiring elucidation in US non-Hispanic Black and West African populations.

Indexed as

Black or African AmericanBreast NeoplasmsAdolescentAdultAgedCase-Control StudiesCross-Sectional StudiesFemaleGhanaHumansIncidenceMiddle AgedUnited StatesWhiteYoung Adult

Identifiers

PMID41082230
PMCPMC12519306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.